Overview

Study of Alimta in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) Who Have Had Prior Platinum Based Chemotherapy

Status:
Completed

Trial end date:
2012-01-01

Target enrollment:

Participant gender:

Summary

This is a pilot phase II study of locally advanced or metastatic nasopharyngeal carcinoma (NPC) with the single drug Alimta. The objective of this study is to assess efficacy and safety profiles of Alimta as 2nd line treatment for patients with advanced NPC.

Phase:

Phase 2

Details

Lead Sponsor:

Sun Yat-sen University

Collaborator:

Eli Lilly and Company

Treatments:

Pemetrexed